ELMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Buy now: the primary trend is bullish (SMA_5 > SMA_20 > SMA_200) with a positive, expanding MACD histogram, and fundamentals are accelerating (Q1 strong YoY growth).", "Options positioning is extremely call-skewed (very low put/call open interest and zero put volume), which supports bullish sentiment into the next catalyst (earnings on 2026-02-10).", "Near-term probability model suggests slight weakness over the next day/week but a positive 1-month bias; given you\u2019re unwilling to wait for an optimal entry, current levels near the pivot (~29.02) are an acceptable buy zone."]
["Trend: Bullish structure with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200), suggesting an established uptrend despite today\u2019s -2.62% pullback to 29.42.", "Momentum: MACD histogram at 0.199 and expanding above zero = bullish momentum strengthening.", "RSI (6): 72.50 (elevated). This implies short-term overbought/extended conditions, increasing odds of a brief consolidation or dip even within an uptrend.", "Key levels: Pivot 29.022 (current price 29.42 is just above). Resistance R1 30.37 then R2 31.203. Support S1 27.673 then S2 26.84.", "Pattern-based outlook (similar candlesticks): ~60% chance of -1.99% next day, -0.86% next week, +3.83% next month (short-term chop, medium-term positive)."]
could extend the trend if growth/operating leverage persists.", "Recent quarter momentum: Strong YoY revenue, EPS, and net income growth suggests operational traction.", "Analyst support: Roth Capital reiterates Buy and raised target to 36, citing share gains and underdiagnosed market opportunity."]
["Short-term extension risk: RSI_6 at ~72.5 suggests the stock can pull back/consolidate near-term even if the primary trend remains up.", "Event risk: Earnings in a few days increases gap risk; options IV is elevated going into the print.", "No fresh news flow in the last week: without new catalysts, price can drift or mean-revert in the very short run."]
["Latest quarter (2026/Q1): Revenue 16,887,000 (+15.13% YoY) showing solid top-line growth.", "Profitability: Net income 2,136,000 (+44.91% YoY) indicating expanding operating leverage.", "EPS: 0.25 (+56.25% YoY) shows earnings growth outpacing revenue growth (positive mix/efficiency signal).", "Margins: Gross margin 78.15% (down 0.24% YoY) is a slight negative, but the decline is minimal relative to the earnings acceleration."]
["Recent action: (2025-11-13) Roth Capital raised price target to $36 from $35 and maintained a Buy rating after Q1 beat and reiterated double-digit top-line growth goals.", "Wall Street pro view (pros): Continued share gains in its niche device market; underdiagnosed end-market supports runway; evidence of operating leverage.", "Wall Street pro view (cons): Limited broader coverage/data in the provided set; with earnings upcoming and elevated IV, timing risk is higher even with a constructive long thesis.", "Influential/political trading: No recent congress trading data available in the last 90 days; hedge funds and insiders flagged as Neutral with no significant recent trend."]
